Settlements Reached in Levaquin Personal Injury MDL

Bloomberg Law’s combination of innovative analytics, research tools and practical guidance provides you with everything you need to be a successful litigator.

Some 845 plaintiffs in the federal Levaquin multidistrict litigation have reached settlements with manufacturer Johnson & Johnson over alleged personal injury claims, according to an Oct. 30 filing in the proceedings (Levaquin Products Liability Litigation, In re, D. Minn., No. 08-1943, status report filed 10/30/12).

Plaintiffs sued Johnson & Johnson and subsidiary Ortho-McNeil Janssen Pharmaceuticals Inc., alleging the antibiotic causes tendon rupture. Federal suits were consolidated in the U.S. District Court for the District of Minnesota in 2008.

Settlement is proceeding in several groups, an Oct. 30 status conference report said. The first group involves about 845 plaintiffs, represented by a small number of firms, who reached a settlement in September. The plaintiffs anticipate the agreement will be finalized in the next two weeks, the report said.

The second settlement group involves about 130 plaintiffs, represented by other firms, who are interested in participating in the settlement reached by the first group.

A third group involves plaintiffs represented by counsel who have a small number of cases in the MDL. This group also includes plaintiffs who are not working through MDL counsel, but have reached out directly to defendants to discuss settlement options. Some 60 plaintiffs are involved in the third group, the report said.

The terms of the settlements are confidential, plaintiffs' attorney Ronald Goldser of Zimmerman Reed told BNA Nov. 6.

The parties also are working toward developing a standardized settlement protocol, the report said.

There are 1,793 cases in the federal MDL, according to a Sept. 5 statistics report. The status conference report is at

Request Litigation on Bloomberg Law